Key result
Reticulated platelets are increased in patients with coronary artery disease and stroke, and their circulating proportion is associated with the likelihood of ischaemic events.
Reticulated platelets may serve as a marker for increased risk of ischemic events and hypo-responsiveness to anti-platelet therapy in patients with atherothrombotic disease.
May support reticulated platelets as an ischemic risk marker in CAD and stroke; leaves open prospective validation for clinical use.
Platelets play an essential role in the pathophysiology of atherothrombosis. Reticulated platelets (RPs) are the youngest platelet population in the circulation; their presence is an indicator of platelet turnover. Circulating levels of RPs are increased in patients with coronary artery disease and stroke. Preliminary indications are that the proportion of circulating RP is associated with the likelihood of ischaemic events such as acute coronary syndrome and stroke. Plausible mechanisms include: (1) increased participation of these platelets in thrombosis due to messenger ribonucleic acid that may be translated to active proteins, (2) lack of exposure to anti-platelet drugs since they are newly released from the bone marrow or (3) their presence is a non-specific marker of inflammation. In this state-of-the-art review, we discuss the implication of RP in coronary artery disease and in hypo-responsiveness to the most commonly used anti-platelet drugs.
No takes yet. Share an insight, caveat, or question.
Hannawi et al. (2018) conducted a review in Coronary artery disease and stroke. Reticulated platelets was evaluated. Reticulated platelets are increased in patients with coronary artery disease and stroke, and their circulating proportion is associated with the likelihood of ischaemic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: